Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Binh Dinh Pharmaceutical And Medical Equipment JSC Debt-to-Asset Chart
Binh Dinh Pharmaceutical And Medical Equipment JSC Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Binh Dinh Pharmaceutical And Medical Equipment JSC Debt-to-Asset vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) has a Debt-to-Asset of 0.09 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Binh Dinh Pharmaceutical And Medical Equipment JSC and its competitors.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-Asset too high?
Binh Dinh Pharmaceutical And Medical Equipment JSC's current Debt-to-Asset is 0.09. Overall, Binh Dinh Pharmaceutical And Medical Equipment JSC has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-Asset compare to ZTS?
Binh Dinh Pharmaceutical And Medical Equipment JSC's Debt-to-Asset of 0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Binh Dinh Pharmaceutical And Medical Equipment JSC and its competitors. Binh Dinh Pharmaceutical And Medical Equipment JSC's current Debt-to-Asset is 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC stock overvalued right now?
Based on GuruFocus' analysis, Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) is currently considered Fairly Valued. The stock's GF Value™ is ₫52,230.11, compared to a current price of ₫49,250.00 — trading 5.7% below its estimated fair value. The current Debt-to-Asset is 0.09. Binh Dinh Pharmaceutical And Medical Equipment JSC's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD), the current Debt-to-Asset is 0.09 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Binh Dinh Pharmaceutical And Medical Equipment JSC (STC:DBD) Overvalued in 2026?
Based on GuruFocus' analysis, Binh Dinh Pharmaceutical And Medical Equipment JSC stock appears to be undervalued.
The current stock price of ₫49,250.00 is trading 5.7% below its estimated GF Value™ of ₫52,230.11.
GuruFocus considers Binh Dinh Pharmaceutical And Medical Equipment JSC to be Fairly Valued.
Key valuation signals for STC:DBD:
Debt-to-Asset: 0.09
GF Value™: ₫52,230.11 vs. price of ₫49,250.00 (5.7% below fair value)
No single metric tells the full story. See the STC:DBD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Binh Dinh Pharmaceutical And Medical Equipment JSC is a pharmaceutical company. The company is engaged in production and trade of pharmaceutical products, medicinal herbs, pharmaceutical and medical equipment.
80GF Score
Get the complete analysis for STC:DBD
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBD has been successfully added to your 
